Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Blood Adv (2021) 5 (16): 3163–3173.

https://doi.org/10.1182/bloodadvances.2020003829

Published: 2021

Journal Articles

Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.

Blood Adv (2021) 5 (13): 2751.

https://doi.org/10.1182/bloodadvances.2021005191

Published: 2021

Journal Articles

Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis

Blood Adv (2021) 5 (5): 1452–1462.

https://doi.org/10.1182/bloodadvances.2020003614

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

Blood Adv (2021) 5 (5): 1442–1451.

https://doi.org/10.1182/bloodadvances.2020003444

Published: 2021

Includes: Supplemental data

Journal Articles

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark L. Heaney, Casey O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann

Blood Adv (2020) 4 (18): 4282–4291.

https://doi.org/10.1182/bloodadvances.2020002662

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, Barbara Mora, Emmanuelle Verger, Nabih Maslah, Aurelie Plessier, Pierre-Emmanuel Rautou, Isabelle Ollivier-Hourman, Victor De Ledinghen, Odile Goria, Christophe Bureau, Claudia Siracusa, Dominique Valla, Stephane Giraudier, Francesco Passamonti, Jean-Jacques Kiladjian

Blood Adv (2020) 4 (15): 3708–3715.

https://doi.org/10.1182/bloodadvances.2020002414

Published: 2020

Includes: Supplemental data

Journal Articles

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio, Mrinal M. Patnaik, Ayalew Tefferi, Alessandro M. Vannucchi, Paola Guglielmelli

Blood Adv (2020) 4 (15): 3677–3687.

https://doi.org/10.1182/bloodadvances.2020002175

Published: 2020

Includes: Supplemental data

Journal Articles

Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv. 2020;4(8):1792-1800.

Blood Adv (2020) 4 (14): 3315.

https://doi.org/10.1182/bloodadvances.2020002897

Published: 2020

Journal Articles

Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study

Vikas Gupta, Denise Wolleschak, Hans Hasselbalch, Alessandro Maria Vannucchi, Steffen Koschmieder, Francisco Cervantes, Yang Li, Tuochuan Dong, Monika Wroclawska, Savita Bharathy, Claire Harrison

Blood Adv (2020) 4 (13): 3063–3071.

https://doi.org/10.1182/bloodadvances.2019001212

Published: 2020

Includes: Supplemental data

Journal Articles

Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice

Veronika Lysenko, Nicole Wildner-Verhey van Wijk, Kathrin Zimmermann, Marie-Christine Weller, Marco Bühler, Mattheus H. E. Wildschut, Patrick Schürch, Christine Fritz, Ulrich Wagner, Laura Calabresi, Bethan Psaila, Richard A. Flavell, Alessandro M. Vannucchi, Adam J. Mead, Peter J. Wild, Stefan Dirnhofer, Markus G. Manz, Alexandre P. A. Theocharides

Blood Adv (2020) 4 (11): 2477–2488.

https://doi.org/10.1182/bloodadvances.2019001364

Published: 2020

Includes: Supplemental data

Journal Articles

Survival following allogeneic transplant in patients with myelofibrosis

Krisstina Gowin, Karen Ballen, Kwang Woo Ahn, Zhen-Huan Hu, Haris Ali, Murat O. Arcasoy, Rebecca Devlin, Maria Coakley, Aaron T. Gerds, Michael Green, Vikas Gupta, Gabriela Hobbs, Tania Jain, Malathi Kandarpa, Rami Komrokji, Andrew T. Kuykendall, Kierstin Luber, Lucia Masarova, Laura C. Michaelis, Sarah Patches, Ashley C. Pariser, Raajit Rampal, Brady Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Vaibhav Agrawal, Mahmoud Aljurf, Miguel Angel Diaz, Belinda R. Avalos, Ulrike Bacher, Asad Bashey, Amer M. Beitinjaneh, Jan Cerny, Saurabh Chhabra, Edward Copelan, Corey S. Cutler, Zachariah DeFilipp, Shahinaz M. Gadalla, Siddhartha Ganguly, Michael R. Grunwald, Shahrukh K. Hashmi, Mohamed A. Kharfan-Dabaja, Tamila Kindwall-Keller, Nicolaus Kröger, Hillard M. Lazarus, Jane L. Liesveld, Mark R. Litzow, David I. Marks, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Attaphol Pawarode, Jacob M. Rowe, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Melhem Solh, Roni Tamari, Leo F. Verdonck, Jean A. Yared, Edwin Alyea, Uday Popat, Ronald Sobecks, Bart L. Scott, Ryotaro Nakamura, Ruben Mesa, Wael Saber

Blood Adv (2020) 4 (9): 1965–1973.

https://doi.org/10.1182/bloodadvances.2019001084

Published: 2020

Includes: Supplemental data

Journal Articles

Fedratinib in myelofibrosis

Ann Mullally, John Hood, Claire Harrison, Ruben Mesa

Blood Adv (2020) 4 (8): 1792–1800.

https://doi.org/10.1182/bloodadvances.2019000954

Published: 2020

Journal Articles

Guidance on changing therapy choice in myelofibrosis

Donal P. McLornan, Claire N. Harrison

Blood Adv (2020) 4 (4): 607–610.

https://doi.org/10.1182/bloodadvances.2019001426

Published: 2020

Journal Articles

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Blood Adv (2019) 3 (21): 3196–3200.

https://doi.org/10.1182/bloodadvances.2019000646

Published: 2019

Includes: Supplemental data

Journal Articles

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI

Naranie Shanmuganathan, Susan Branford, Timothy P. Hughes, Devendra Hiwase

Blood Adv (2019) 3 (3): 370–374.

https://doi.org/10.1182/bloodadvances.2018027516

Published: 2019

Includes: Supplemental data

Journal Articles

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

Blood Adv (2019) 3 (1): 83–95.

https://doi.org/10.1182/bloodadvances.2018026658

Published: 2019

Includes: Supplemental data

Journal Articles

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells

Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing Qiu, Fei Ye, Jane Houldsworth, Kevin Eng, Fei Huang, Ronald Hoffman

Blood Adv (2018) 2 (18): 2378–2388.

https://doi.org/10.1182/bloodadvances.2018022012

Published: 2018

Includes: Supplemental data

Journal Articles

The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis

Jiajing Qiu, Mohamed E. Salama, Cing Siang Hu, Yan Li, Xiaoli Wang, Ronald Hoffman

Blood Adv (2018) 2 (10): 1130–1145.

https://doi.org/10.1182/bloodadvances.2017015073

Published: 2018

Includes: Supplemental data

Journal Articles

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Blood Adv (2017) 1 (20): 1729–1738.

https://doi.org/10.1182/bloodadvances.2017009530

Published: 2017

Includes: Supplemental data

Journal Articles

Therapy-related myelofibrosis does not appear to exist

Lucia Masarova, Gabriele Todisco, Taghi Manshouri, Kate J. Newberry, Jorge E. Cortes, Hagop M. Kantarjian, Zeev Estrov, Srdan Verstovsek

Blood Adv (2017) 1 (14): 863–866.

https://doi.org/10.1182/bloodadvances.2017007369

Published: 2017

NARROW

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.

Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv. 2020;4(8):1792-1800.

Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study

Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice

Survival following allogeneic transplant in patients with myelofibrosis

Fedratinib in myelofibrosis

Guidance on changing therapy choice in myelofibrosis

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells

The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Therapy-related myelofibrosis does not appear to exist

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only